News‎ > ‎

Viamet Drug Candidate VT-1161

The commercial promise of the drug candidate VT-1161 is recognised in the press release below:

http://www.viamet.com/announcement/press-release_VT-1161-Acquisition_FINAL.pdf


The Centre for Cytochrome P450 Biodiversity played an important role in identifying the mode of action of this first example of a tetrazole antifungal compound and saw the complete selectivity for the fungal target compared to human enzyme.  We are excited at the potential impact of this research moving into the pharmacy after Phase 3 trials.